Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteers
In brief
The primary objective of the study is to assess the safety and tolerability of a single dose of subcutaneous (SC) or intravenous (IV) administered fasinumab in healthy Japanese subjects.
Key facts
- Study ID
- NCT02516618
- Run by
- Regeneron Pharmaceuticals
- People needed
- 72
- Starts
- 2015-07-01
- Expected to finish
- 2016-02-01
- Last updated by the study team
- 2016-05-12
Who can join
Age: 20 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Glendale, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.